secwatch / observer
8-K filed November 27, 2023, 6:59 PM ET ticker RSSS CIK 0001386301
M&A confidence high sentiment positive materiality 0.85

Research Solutions acquires AI platform scite for $14.8M; adds $3.6M in subscription revenue

Research Solutions, Inc.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Research Solutions, Inc. entered into Agreement of Merger and Plan of Reorganization with Scite, Inc. valued at Closing Consideration consisting of cash, stock, debt payoff, escrow, holdbacks, and earnout up to $ (effective 2023-11-24).

Action
entry
Agreement
merger
Counterparty
Scite, Inc.
Value
Closing Consideration consisting of cash, stock, debt payoff, escrow, holdbacks, and earnout up to $
Effective
2023-11-24
Exact text from the filing
On November 24, 2023, Research Solutions, Inc., a Nevada corporation (the “ Registrant ”), Research Solutions Acquisition 2, LLC, a Delaware limited liability company and a wholly-owned subsidiary of the Registrant (“ Merger Sub ”), Scite, Inc., a Delaware corporation (“ Scite ”), and Shareholder Representative Services LLC, a Colorado limited liability company, solely in its capacity as the representative, agent and attorney-in-fact of Scite’s securityholders (the “ Stockholder Representative ”), entered into an Agreement of Merger and Plan of Reorganization (the “ Merger Agreement ”), pursuant to which Scite will merge with and into Merger Sub (the “ Merger ”), with Merger Sub continuing its existence under the name “Scite, LLC” (the “ Surviving Entity ”) as the surviving entity after the Merger and a wholly-owned subsidiary of the Registrant.
View on SEC.gov

Browse all material agreements →

Research Solutions, Inc. filing history →

Source: SEC EDGAR
accession 0001104659-23-121108
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.